Mirum’s Livmarli Achieves Primary Endpoint in Phase 3 EXPAND Study by Chad Birt| Published on: Nov 2, 2026

Mirum’s Livmarli Achieves Primary Endpoint in Phase 3 EXPAND Study by Chad Birt| Published on: Nov 2, 2026 Mirum Pharmaceuticals recently announced positive topline results from its phase 3 EXPAND study, evaluating Livmarli (maralixibat) for cholestatic pruritus in patients six months and older with ultra-rare cholestatic liver diseases. Jennifer Vittorio, MD, an EXPAND investigator, an Associate Professor of Pediatrics, and the Medical Director of Pediatric Liver Transplantation at NYU Langone Health, discusses the findings. https://checkrare.com/mirums-livmarli-achieves-primary-endpoint-in-phase-3-expand-study/